Sensitization and Desensitization in Vascularized Composite Allotransplantation
- PMID: 34456906
- PMCID: PMC8385557
- DOI: 10.3389/fimmu.2021.682180
Sensitization and Desensitization in Vascularized Composite Allotransplantation
Abstract
Vascularized composite allotransplantation (VCA) is a field under research and has emerged as an alternative option for the repair of severe disfiguring defects that result from severe tissue loss in a selected group of patients. Lifelong immunosuppressive therapy, immunosuppression associated complications, and the effects of the host immune response in the graft are major concerns in this type of quality-of-life transplant. The initial management of extensive soft tissue injury can lead to the development of anti-HLA antibodies through injury-related factors, transfusion and cadaveric grafting. The role of antibody-mediated rejection, donor-specific antibody (DSA) formation and graft rejection in the context of VCA still remain poorly understood. The most common antigenic target of preexisting alloantibodies are MHC mismatches, though recognition of ABO incompatible antigens, minor histocompatibility complexes and endothelial cells has also been shown to contribute to rejection. Mechanistically, alloantibody-mediated tissue damage occurs primarily through complement fixation as well as through antibody-dependent cellular toxicity. If DSA exist, activation of complement and coagulation cascades can result in vascular thrombosis and infarction and thus rejection and graft loss. Both preexisting DSA but especially de-novo DSA are currently considered as main contributors to late allograft injury and graft failure. Desensitization protocols are currently being developed for VCA, mainly including removal of alloantibodies whereas treatment of established antibody-mediated rejection is achieved through high dose intravenous immunoglobulins. The long-term efficacy of such therapies in sensitized VCA recipients is currently unknown. The current evidence base for sensitizing events and outcomes in reconstructive transplantation is limited. However, current data show that VCA transplantation has been performed in the setting of HLA-sensitization.
Keywords: antibody-mediated rejection; burns; desensitization; face transplantation; hand transplantation; sensitization; vascular composite allotransplantation.
Copyright © 2021 Moris and Cendales.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation.Transplantation. 2018 Apr;102(4):593-600. doi: 10.1097/TP.0000000000002070. Transplantation. 2018. PMID: 29298238
-
Costimulation Blockade in Vascularized Composite Allotransplantation.Front Immunol. 2020 Sep 17;11:544186. doi: 10.3389/fimmu.2020.544186. eCollection 2020. Front Immunol. 2020. PMID: 33042138 Free PMC article. Review.
-
Sensitization and desensitization of burn patients as potential candidates for vascularized composite allotransplantation.Burns. 2016 Mar;42(2):246-57. doi: 10.1016/j.burns.2015.05.019. Epub 2015 Sep 29. Burns. 2016. PMID: 26392022 Review.
-
Donor-specific antibodies and antibody-mediated rejection in vascularized composite allotransplantation.Curr Opin Organ Transplant. 2016 Oct;21(5):510-5. doi: 10.1097/MOT.0000000000000349. Curr Opin Organ Transplant. 2016. PMID: 27517505 Review.
-
Pre-transplant management and sensitisation in vascularised composite allotransplantation: A systematic review.J Plast Reconstr Aesthet Surg. 2020 Sep;73(9):1593-1603. doi: 10.1016/j.bjps.2020.05.010. Epub 2020 May 19. J Plast Reconstr Aesthet Surg. 2020. PMID: 32475735
Cited by
-
Urinary bladder transplantation in humans - current status and future perspectives.Nat Rev Urol. 2025 Mar;22(3):175-186. doi: 10.1038/s41585-024-00935-2. Epub 2024 Sep 20. Nat Rev Urol. 2025. PMID: 39304780 Review.
-
Potential Roles of miRNAs in Acute Rejection for Vascularized Composite Allotransplantation.J Inflamm Res. 2022 Oct 28;15:6021-6030. doi: 10.2147/JIR.S383628. eCollection 2022. J Inflamm Res. 2022. PMID: 36330168 Free PMC article.
-
Novel Human Umbilical Di-Chimeric (HUDC) cell therapy for transplantation without life-long immunosuppression.Stem Cell Investig. 2023 Aug 14;10:16. doi: 10.21037/sci-2023-024. eCollection 2023. Stem Cell Investig. 2023. PMID: 37614644 Free PMC article.
-
Immunogenicity and tolerance induction in vascularized composite allotransplantation.Front Transplant. 2024 Feb 13;3:1350546. doi: 10.3389/frtra.2024.1350546. eCollection 2024. Front Transplant. 2024. PMID: 38993748 Free PMC article. Review.
-
Cellular activation pathways and interaction networks in vascularized composite allotransplantation.Front Immunol. 2023 May 17;14:1179355. doi: 10.3389/fimmu.2023.1179355. eCollection 2023. Front Immunol. 2023. PMID: 37266446 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials